Covidien (COV) Tops Q4 EPS by 10c; Gives Slight Boost to FY12 Revs Outlook
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Price: $106.71 --0%
Financial Fact:
Cost of goods sold: 1.04B
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Cost of goods sold: 1.04B
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Covidien (NYSE: COV) reported Q4 EPS of $1.13, $0.10 better than the analyst estimate of $1.03. Revenue for the quarter came in at $2.9 billion versus the consensus estimate of $2.92 billion.
On an operational basis, excluding the impact of foreign exchange, Covidien now estimates that total Company sales in FY12 will increase 3% to 5% in fiscal 2012, about one percentage point above its prior guidance.
For earnings history and earnings-related data on Covidien (COV) click here.
On an operational basis, excluding the impact of foreign exchange, Covidien now estimates that total Company sales in FY12 will increase 3% to 5% in fiscal 2012, about one percentage point above its prior guidance.
For earnings history and earnings-related data on Covidien (COV) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
